Tag: head of development

Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.¹ REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.¹ These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s (ADA) 85th Scientific Sessions and published in NEJM.

NYU IHIF 2026 Takes Place May 31-June 2 at the Marriott Marquis in New York

The Supervisory Board of Enefit Green has appointed Donatas Celešius as Member of the Management Board and Head of Development at Enefit Green. His three-year term will commence on 7 June 2025.
Celešius has been with Enefit Green since 2018, holding several senior positions, including General Manager and Head of Development for the Lithuanian unit. Prior to joining Enefit Green, he worked on wind energy development at Nelja Energia and led major landfill biogas projects at Proto Paslaugos in Lithuania. 
Celešius holds a master’s degree in information and communication management from Vilnius University and a bachelor’s degree in international business management.